Innovations in Pulmonary Arterial Hypertension

CE / CME

Redefining Relief: Emerging Innovations in the Management of Pulmonary Arterial Hypertension

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: September 04, 2024

Expiration: September 03, 2025

Vallerie V. McLaughlin
Vallerie V. McLaughlin, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Your patient with HFrEF and RV dysfunction experiences exertional dyspnea. You suspect PH and an RHC confirms that diagnosis. How would you classify this patient’s PH and qualify their mortality risk? 

2.

In the phase III STELLAR trial of patients with PAH receiving stable background therapy, compared to placebo, sotatercept resulted in:

3.

An individual is newly diagnosed with PAH. Their REVEAL 2.0 score is 8 (intermediate risk), they are nonvasoreactive, and have no comorbidities. Which of the following would be the best initial treatment?